Discover 3,465 paid clinical trials in Santa Monica, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,465
Optimizing PrEP Uptake and Adherence Among Male Sex Workers
for
Prevention
Location: Los Angeles CA, Providence RI
Sponsor: Brown University
Sex: Male
Age: 18+
Code: NCT05736614
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
for
Non Small Cell Lung Cancer
Location: Los Angeles CA, Beverly Hills CA, Orange CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312137
Phase3, Recruiting
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
for
Non-small Cell Lung Cancer
Location: Los Angeles CA, Orange CA, Newport Beach CA, Tucson AZ,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06077760
Phase3, Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
for
Alcohol Use Disorder
Location: Los Angeles CA, Riverside CA, San Diego CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07219953
Phase3, Recruiting
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
for
Angelman Syndrome
Location: Los Angeles CA, San Diego CA, Aurora CO, Vancouver,
Sponsor: Ionis Pharmaceuticals, Inc.
Sex: All
Age: 2 - 50
Code: NCT06914609
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
for
Parkinsons Disease (PD)
Location: Los Angeles CA, Orange CA, Palo Alto CA, Sun City AZ,
Sponsor: BlueRock Therapeutics
Sex: All
Age: 45 - 70+
Code: NCT06944522
Phase3, Recruiting
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
for
Macular Degeneration
Location: Los Angeles CA
Sponsor: University of California, Los Angeles
Sex: All
Age: 50+
Code: NCT00996684
Phase2, Recruiting
fNIRS for Disorders of Consciousness
for
Disorders of Consciousness Due to Severe Brain Injury,
Location: Los Angeles CA
Sponsor: University of California, Los Angeles
Sex: All
Age: 18+
Code: NCT07485361
Recruiting
Effects of Acupuncture on Symptoms of Stable Angina
for
Angina, Stable
Location: Los Angeles CA
Sponsor: University of California, Los Angeles
Sex: All
Age: 21+
Code: NCT06311461
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
for
Interstitial Lung Disease
Location: Los Angeles CA, San Diego CA, Salt Lake City UT,
Sponsor: aTyr Pharma, Inc.
Sex: All
Age: 18+
Code: NCT05892614
Phase2, Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
for
Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Location: Los Angeles CA, Long Beach CA, Duarte CA, Irvine CA,
Sponsor: Ascentage Pharma Group Inc.
Sex: All
Age: 18+
Code: NCT06423911
Phase3, Recruiting
Towards Restoring Complex Movement After Paralysis: Algorithm Development With Healthy Participants
for
Movement Disorders, Neurorehabilitation,
Location: Los Angeles CA
Sponsor: University of California, Los Angeles
Sex: All
Age: 18+
Code: NCT07236892
Recruiting
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
for
Peripheral T-cell Lymphoma
Location: Los Angeles CA, Gilbert AZ, Dallas TX, Westwood KS,
Sponsor: CerRx, Inc.
Sex: All
Age: 18+
Code: NCT02495415
Phase2, Recruiting
Longitudinal Study of Urea Cycle Disorders
for
Brain Diseases, Metabolic, Inborn,
Location: Los Angeles CA, Stanford CA, Portland OR, Aurora CO,
Sponsor: Andrea Gropman
Sex: All
Age: 0+
Code: NCT00237315
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors